Faber — 2013 Investments
1 investments dated 2013 · listed companies and verified rows first · show all
Minoryx Therapeuticsminoryx.cominSeries A · Apr 2013 · $2M
Minoryx is a registration-stage biotech company developing novel therapies for severe, orphan genetic diseases of the central nervous system, with a lead compound (leriglitazone) in clinical trials for conditions including cerebral adrenoleukodystrophy, Friedreich's Ataxia, and Rett syndrome.
BiotechDeep TechHealthtechMedical DevicesMataró, ES
Marc Martinell(Co-Founder & Chief Executive Officer)in
Co-investorsChiesi VenturesCriteria Bio VenturesFund+Invivo Capital PartnersKurma PartnersRoche Venture Fund+2 more
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.